Tezacaftor

Overview

Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CFTR

Product Information

• Catalog No.: HY-15448
• CAS No.: 1152311-62-0
• Molecular Formula: C26H27F3N2O6
• Molecular Weight: 520.50
• Purity: 99.85%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
• Availability: In-stock

Source

Original product source